Amgen says Imdelltra combo reduced risk of death by 58% in first-line lung cancer
AMGN•Amgen said Imdelltra plus durvalumab reduced the risk of death by 58% in first-line extensive-stage small cell lung cancer and extended median overall survival to 21.1 months, versus 12.7 months with durvalumab alone.
1. Trial results
Amgen said nearly 80% of patients receiving Imdelltra plus Imfinzi were alive at one year, compared with 53% of patients receiving durvalumab alone, and progression-free survival more than tripled. Grade 3 or higher adverse events occurred in 20.9% of patients on the combination, versus 10.8% on Imfinzi alone.
